Large-scale production of lentiviral vector in a closed system hollow fiber bioreactor. by Sheu, Jonathan et al.
UC Davis
UC Davis Previously Published Works
Title
Large-scale production of lentiviral vector in a closed system hollow fiber bioreactor.
Permalink
https://escholarship.org/uc/item/1797s3zt
Authors
Sheu, Jonathan
Beltzer, Jim
Fury, Brian
et al.
Publication Date
2015
DOI
10.1038/mtm.2015.20
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Citation: Molecular Therapy — Methods & Clinical Development (2015) 2, 15020; doi:10.1038/mtm.2015.20 
© 2015 The American Society of Gene & Cell Therapy All rights reserved 2329-0501/15
www.nature.com/mtm
INTRODUCTION
Clinical gene therapy has historically been plagued with many 
obstacles, primarily due to the inefficient nature of gene modifi-
cation by physical means of DNA transfer. Beginning in the 1980s, 
hematopoietic stem cell and T-cell gene therapy1–3 for the treatment 
of leukemia and severe combined immunodeficiency (SCID) were 
developed.4,5 Research and clinical trials utilizing non-viral DNA 
delivery methods such as lipofection,6 electroporation,7 and simple 
naked DNA injections8 yielded some promising results, but the lev-
els of gene expression were consistently low.9 However, with the 
emergence of gamma-retroviral vectors based on the Moloney leu-
kemia virus as gene delivery vehicles in the late 1980s,10 gene ther-
apy obtained a powerful tool. These vectors allowed for an increase 
in the amount of DNA to be transferred, permanent gene modifica-
tion due to integration into the target cells’ DNA and the possibil-
ity of a lasting treatment or even cure for genetic diseases due to 
durable gene expression.11 Subsequently, γ-retroviral vectors were 
successfully used to cure children of adenosine deaminase (ADA) 
SCID applying stem cell gene therapy.12 γ-retroviral vectors, how-
ever, have the drawback of only being able to transduce dividing 
cells, and they also preferentially integrate into transcriptional start 
regions of active genes. This integration pattern can potentially lead 
to insertional oncogenesis due to the activation of nearby onco-
genes. A new development in the late 1990s was the emergence 
of lentiviral vectors based on HIV. These vectors are not limited to 
transducing dividing cells, and do not preferentially integrate into 
transcriptional start regions of active genes, making them safer. 
However, multiple-copy and semi-random vector insertions into 
the target cells still pose the potential risk of insertional mutagen-
esis. To curb this risk, both lowering the transferred copy number 
and deleting the Moloney leukemia virus LTR U3 enhancer to create 
a self-inactivating γ-retrovirus13 could lead to lower chances of inser-
tional mutagenesis. Nevertheless, due to their advantages, lentiviral 
vectors are being used in clinical trials worldwide.
A relatively recent development is the generation of induced plu-
ripotent stem cells (iPSCs).14 Lentiviral vectors can be used to insert 
the genes for early acting transcription factors such as Sox2, Klf4, 
c-myc, and Oct4, into somatic cells to revert them back into a plu-
ripotent state. While considerable efforts have gone into reverting 
somatic cells back to not only a phenotypically but also a genotypi-
cally similar state as embryonic stem cells,15,16 epigenetic memory is 
still a challenge for iPSC differentiation.17,18 In spite of this drawback, 
iPSCs are seen as an excellent target for gene correction of cells 
coming from patients with genetic diseases.19,20 Lentiviral vectors, 
due to their large gene carrying capacity (up to 9kb, as opposed to 
5kb for adeno-associated viral vectors)21–23 and high transduction 
efficiency are still a popular method of iPSC generation; however, for 
clinical purposes, these vectors need to be removable after reliable 
iPSC generation, otherwise the early acting transcription factors will 
continue to be produced. Such a removable lentiviral vector can 
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Lentiviral vectors are widely used in the field of gene therapy as an effective method for permanent gene delivery. While current 
methods of producing small scale vector batches for research purposes depend largely on culture flasks, the emergence and 
popularity of lentiviral vectors in translational, preclinical and clinical research has demanded their production on a much larger 
scale, a task that can be difficult to manage with the numbers of producer cell culture flasks required for large volumes of vector. 
To generate a large scale, partially closed system method for the manufacturing of clinical grade lentiviral vector suitable for the 
generation of induced pluripotent stem cells (iPSCs), we developed a method employing a hollow fiber bioreactor traditionally 
used for cell expansion. We have demonstrated the growth, transfection, and vector-producing capability of 293T producer cells in 
this system. Vector particle RNA titers after subsequent vector concentration yielded values comparable to lentiviral iPSC induction 
vector batches produced using traditional culture methods in 225 cm2 flasks (T225s) and in 10-layer cell factories (CF10s), while 
yielding a volume nearly 145 times larger than the yield from a T225 flask and nearly three times larger than the yield from a CF10. 
Employing a closed system hollow fiber bioreactor for vector production offers the possibility of manufacturing large quantities of 
gene therapy vector while minimizing reagent usage, equipment footprint, and open system manipulation.
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be created by use of the Cre-lox system.24 By exposing transduced 
cells to cre-recombinase, the integrated vector can be excised at the 
loxP sites it carries. As an example, this system was used to gener-
ate iPSCs from patients with a genetic disease such as recessive dys-
trophic epidermolysis bullosa that could be gene corrected using 
homologous recombination and then differentiated into keratino-
cytes.25 In the future, such gene corrected differentiated cells can be 
expanded greatly and used in autologous, clinical transplantation 
procedures to replace diseased tissue with healthy tissue.
Lentiviral vector is mostly generated by use of a transient 
transfection system applying plasmids and producer cells. Both 
three and four plasmid systems are in use, where the structural, 
polymerase, envelope and genes of interest are split up into mul-
tiple plasmids and transfected into a producer cell line such as 
293T cells, a highly transfectable derivative of human embryonic 
kidney cells that contains the SV40 T-antigen. Traditional culture 
flask methods for growing producer cells and their subsequent 
transfection using lipofection or calcium phosphate precipitation 
is convenient for small-scale preparations used in basic research; 
however, translational research demanding larger scale toxic-
ity studies also warrants larger volumes of vector while main-
taining a high titer. Large-scale lentiviral vector production can 
become quite cumbersome when flasks are used, as it requires 
the growth and transfection of billions of cells, which can equate 
to 40 or more T225 flasks. 10- and 40-layer cell factories provide 
larger surface areas for cell growth; however, they come with their 
own challenges of cell visualization, uniform cell distribution and 
adequate gas exchange throughout all layers, and an extraordi-
nary volume of media. Achieving a consistently high vector titer 
is also a major challenge for these culture systems.
New methods of large-scale vector production have therefore 
been contemplated, and one of the most prominent concepts is a 
closed system hollow fiber bioreactor. The Terumo Quantum Cell 
Expansion System is a hollow fiber bioreactor designed to expand 
cells to the 109 range in a manageable and compact culture ves-
sel. The Quantum system is comprised of a computer interface and 
a tubing adapter panel containing peristaltic pumps, fluid sensors 
and tubing clamps placed at various locations to control fluid flow. 
The disposable cell expansion set, which contains tubing, inlet bags, 
waste bags and the hollow fiber bioreactor cartridge itself, is man-
ually loaded onto the tubing adapter panel prior to use. This car-
tridge is comprised of 11,100 individual fibers, totaling 2.1 square 
meters of surface area available for cell culture, while occupying a 
total volume of only 180 ml. Additionally, the entire set contains two 
mutually exclusive feed loops—an intracapillary (IC) loop, which 
flows through the fibers’ interiors, and an extracapillary (EC) loop, 
which flows through the space between the fibers. The fibers are 
porous, with the pores being so small that cells cannot be trans-
ported through these pores. Metabolites and fresh nutrients, how-
ever, can be transported through the pores. Each of these loops can 
be accessed independently through selective task programming, 
depending on the tasks required for any particular run. Inlet lines 
coming off the expansion set are available for loading IC media, EC 
media, cells, and reagents; two outlet lines are available for waste 
and cell harvest.
Additional features of the Quantum system include the fol-
lowing: To assess the rate of cell growth, a syringe septum allows 
access to the EC loop for taking media samples. The front door to 
the Quantum system creates an airtight seal that maintains a 37 °C 
environment around the expansion set; internal sensors alert the 
operator if the intra-tubular pressure exceeds 1,000 mm Hg. While 
the Quantum system has been used in studies for both mesen-
chymal stem cell26 and embryonic stem cell (ESC)27 expansions, we 
have shown for the first time that we can utilize the capabilities of 
this system to produce large-scale lentiviral vector with titers com-
parable to those obtained using conventional flask cultures and 
 multi-layer cell factories.
ReSUlTS
Three vector production runs were performed in the hollow-fiber 
bioreactor, each time using identical ratios of the plasmids and 
accompanying reagents as described above. For comparison 
Table 1 Hollow-fiber bioreactor lentiviral vector production 
statistics
First run Second run Third run
Cells seeded 1.00 × 109 1.00 × 109 1.87 × 109
% Viability of seeded cells 97% 97% 98%
Viral titer (vg/ml) 1.915 × 108 2.790 × 108 1.025 × 108
Cells harvested 1.77 × 109 1.77 × 109 2.02 × 109
% Viability of harvested cells 94% 95% 98%
HEK 293T cells were expanded to the 109 range in T225 flasks prior to 
seeding the bioreactor and underwent a partial doubling during the 
expansion period. Cell counts and viability assays were performed before 
and after each run via Trypan Blue exclusion dye in a hemacytometer as 
described. Total particle titers were measured using a qPCR lentivector 
titration kit.
Table 2 Volume and particle yield comparison between lentiviral vector production methods
Mean yield,  
Bioreactora (vg)
Mean yield, per  
T225b (vg)
Mean yield,  
CF10a (vg)
Bioreactor to T225 
Ratiod (viral yield)
Bioreactor to CF10 
Ratiod (viral yield)
3.82 × 109 2.06 × 107 1.75 × 109 185.21 2.18
Mean vector volume,  
Bioreactor (ml)a
Mean vector volume,  
per T225c (ml)
Mean vector volume, 
CF10 (ml)a
Bioreactor to T225 
ratiod (volume)
Bioreactor to CF10 
Ratiod (volume)
20.00 0.14 6.75 145.45 2.96
aMean yields and volumes for large systems (bioreactor, CF10) were calculated by multiplying the titer by the postconcentration volume and averaging the 
resulting values from each run. bMean per T225 flask yields were calculated by multiplying the titer by the postconcentration volume and averaging the resulting 
values, then dividing the total calculated viral output by the number of vessels used in that run. cMean per flask concentrated vector volume was calculated by 
dividing the total volume of the concentrate by the number of vessels used in that run, since the viral supernatant from multiple flasks was required to fill a single 
Centricon Plus-70. dRatio values were calculated by dividing the mean bioreactor yield by the respective mean per flask and mean per CF10 yields.
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 studies, two runs were performed in CF10s. Five runs were per-
formed in T225 flasks as controls. The results of the bioreactor runs 
are summarized in Table 1.
Transfecting and harvesting 293T cells using the hollow fiber 
system does not affect viability
First, we assessed the amount of expansion achieved by using HEK 
293T cells in the pretransfection expansion period as well as cell via-
bility after vector production and cell harvest. Cells were expanded 
in T225 flasks for approximately 6 days in order to obtain roughly 1 
billion cells, which were counted and assayed for initial viability via 
Trypan Blue exclusion prior to seeding the bioreactor. Immediately 
after concluding the 36-hour harvest period and removing the vec-
tor collection bag, the 293T cells were trypsinized and harvest off 
the bioreactor to assess expansion and viability. Harvested cells 
were counted and assayed for viability using the same Trypan Blue 
exclusion method mentioned above. Cell counts pre- and post-run 
show appreciable cell expansion during the 24-hour attachment 
phase. During transfection, we anticipated a decrease in the rate of 
cell division, so a complete doubling was not expected. Viral titer 
was performed on the harvested supernatant via qPCR, and the 
viral genomes per ml (vg/ml) were used to approximate the total 
viral yield (Table 2).
Different manufacturing platforms obtain comparable viral titers
Across all three manufacturing platforms, viral titers achieved fell 
between 1.7 × 108 vg/ml and 2.6 × 108 vg/ml, demonstrating that 
the bioreactor produces titers comparable to those obtained in 
conventional static cultures. This suggests that 293Ts as producer 
cells can easily adapt from conventional static culture platforms 
to a dynamic, constant-perfusion system with a vastly increased 
surface area and small overall volume, such as the hollow-fiber 
bioreactor, and that viral output is not affected by this culture 
environment.
For statistical analysis, due to unequal variance values, Welch’s 
t-test was chosen to compare production methods. In comparing 
the bioreactor to CF10s, a df = 2 was used to calculate a t-score of 
1.3052, yielding a two-tailed P value of 0.15 < P < 0.20, indicating 
that there is no statistically significant difference between the bio-
reactor and CF10 methods with respect to titer. The 95% confidence 
interval for this comparison was calculated to be −4.21 × 108 vg/
ml < μ < 1.76 × 108 vg/ml.
In comparing the bioreactor to T225 flasks, a df = 2 was used to 
calculate a t-score of 0.4758, yielding a two-tailed P value of P > 0.20, 
indicating that there is no statistically significant difference between 
the bioreactor and CF10 methods with respect to titer. The 95% con-
fidence interval for this comparison was calculated to be −2.20 × 108 
vg/ml < μ < 1.49 × 108 vg/ml.
Figure 1  Quantum hollow fiber bioreactor hydraulic layout. This layout details the fluid flow, vessel schematics, and approximate volumes of the 
bioreactor cartridge itself and the accessory tubing system surrounding it. This illustrates the dynamic-perfusion concept of the bioreactor and allows 
one to follow the flow of fluid through the system, permitting the engineering of custom tasks to direct fluid through a specific, user-defined path if 
desired.
Quantum cell expansion system • Hydraulic layout with corresponding fluid volumes
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Viral output from the hollow fiber bioreactor outweighs yields from 
T225 flasks and CF10s
Owing to its largely increased surface area, constant-perfusion 
system, and greater harvest volume capacity, the hollow fiber bio-
reactor’s yield far outweighed that of flasks and CF10s. While the 
number of viral genomes per ml remained comparable between 
platforms, the sheer amount of viral supernatant obtained from 
the bioreactor allowed for greater viral output than either static 
culture platform.
DISCUSSION
Since lentiviral vectors have become important tools for gene 
therapy, particularly for clinical applications of gene therapy, is 
has also become necessary to manufacture affordable and high 
quality lentiviral vector while minimizing reagent use and person-
nel time required. CF10s have previously been explored as culture 
vessels for clinical-grade vector production,28–30 yielding titer val-
ues similar to the ones we achieved. However, the large amount 
of reagents and personnel time required for flask and cell factory 
cultures make these methods cumbersome. To manipulate hun-
dreds of tissue culture flasks inside a biosafety cabinet without 
sterility issues is a huge concern. Cell factories and their open sys-
tem nature also make them contamination prone during repeated 
manipulation. Additionally, large volumes of reagents are needed, 
making vector manufacturing in this system a rather wasteful 
process.
Our results demonstrate that vector particle titers, comparable 
to those attained in flask or cell factory cultures, can be achieved in 
the Quantum system by utilizing the large surface area of a hollow 
fiber bioreactor coupled with media perfusion to efficiently culture 
producer cells while eliminating the need for periodic enzymatic 
passaging. Transient transfection by calcium phosphate precipi-
tation with plasmid ratios similar to those applied in regular flask 
cultures was possible and provided comparable results to flask and 
cell factory cultures. Thus, the potential for automated, compact, 
and efficient production of lentiviral vector becomes a reality with 
the use of this method. While pre- and post-Quantum procedures 
(culturing cells for seeding, reagent preparation, filling of bags, and 
postprocessing) still require a fair amount of open-system manipula-
tion in a biosafety cabinet, the Quantum system itself is designed 
to be functionally closed. Any other procedure in the closed system 
bioreactor can easily be performed in a nonclassified environment 
with minimized footprint and oversight (a maximum of two opera-
tors at any one time was needed for an entire vector manufacturing 
run in our studies).
To assess the capabilities of the cell factory system compared 
to the hollow-fiber system, total particle titers were performed to 
quantify gross particle yields from both platforms. Transducing 
titers were not performed for this study because this work primarily 
focused on comparing the total number of particles achieved, and 
not necessarily the number of transducing units (TU) produced. One 
concern of ours was that transduction efficiency could be affected 
by the presence of cellular debris and envelope protein, so further 
downstream processing beyond Centricon Plus-70 units may be 
required to increase vector purity. We have explored the potential 
of tangential flow filtration as a means of concentrating large vol-
umes of viral vector; while this method is currently not sterile, we 
are striving to develop an aseptic method for large-scale vector 
concentration. With increased vector purity, increased transduc-
tion efficiency becomes more plausible, and tangential flow filtra-
tion is just one of the tools we plan to include in our future studies. 
We have also experimented with polyethylenimine as an alternative 
transfection reagent, which has been in use since the mid-1990s,31 
and polyethylenimine could also have an effect on the resulting len-
tivector’s transduction efficiency. We are currently planning a statis-
tically relevant number of new vector manufacturing experiments 
to measure and optimize infectious titers from lentiviral vectors 
produced in various large-scale platforms, applying the abovemen-
tioned additional purification strategies, which will be presented in 
a future publication.
Figure 2 Viral titer comparison between lentiviral vector production 
methods. The results of the T225 flask and CF10 vector production 
runs were compared with the bioreactor production runs, yielding 
comparable titer values (approximately 1.7 × 108 vg/ml to 2.5 × 108 vg/
ml) across all three production methods. Production in the T225 flasks 
(n = 5) yielded a standard error* of 1.41 × 107 vg/ml; CF10s (n = 2) yielded 
a standard error of 5.75 × 107 vg/ml, and the bioreactor yielded a standard 
error of 7.19 x 107 vg/mL. Variance was calculated by taking the square of 
the standard deviation. *Standard errors of the mean are expressed on 
the graph as error bars.
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Table 3 Transfection reagent mix ratios
Concentration
Per T225 
flask (ml)
Per CF10 
(ml)
Per  
bioreactor (ml)
Sterile H2O N/A 0.707 19.985 41.90
CaCl2 2 mol/l 0.500 14.133 29.70
MgCl2 2 mol/l 0.121 3.420 7.20
HeBS 2× 1.960 55.403 116.60
VSVG 0.25 mg/ml 0.020 0.565 2.4
Δ8.9 1.4 mg/ml 0.018 0.509 2.14
iPSC 0.86 mg/ml 0.029 0.820 3.49
Total volume 3.355 94.835 203.43
Vector production runs in T225 flasks and in CF10s were performed in 
parallel, each time using plasmids and calcium phosphate reagents in the 
above ratios. Plasmid and transfection excipient ratios were determined 
through previous in-house optimization studies. Excipient ratios for 
transfecting cells inside the bioreactor differ due to the restricted volume of 
approximately 180–200 ml inside the IC loop. While plasmid amounts were 
proportionally scaled up from those amounts used in T225 flasks or CF10s, 
precipitation reagent amounts were kept in the same ratios relative to each 
other but in smaller volumes due to the 200 ml volume restriction.
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In terms of output, while our data show that a single bioreac-
tor replaces only approximately three CF10s, the advantages of 
having a fully automated system, with only the need to replace 
media and waste bags, allows for quicker and easier operation as 
well as the possibility of running several Quantums simultane-
ously. Thus, product output from using the Quantum system is 
greatly increased while the required number of man-hours is only 
slightly increased per additional Quantum. In contrast, because 
they require so much manual manipulation, each additional CF10, 
CF40, or other static culture platform warrants a greatly increased 
number of man-hours to produce the same amount of vector. 
Additionally, in order to manually manipulate and incubate a sys-
tem as large as a CF40 requires multiple personnel and a Nunc Cell 
Factory Incubator (Thermo Scientific, Waltham, MA) built specially 
for fitting CF10s and CF40s. Automatically manipulating CF40s 
requires a special “Nunc™ Automatic Cell Factory™ Manipulator 
System” (Thermo Scientific). Both items together cost six times 
more than a single Quantum (see Cost Analysis supplement), 
occupy a much larger footprint and require a large clean/nonclas-
sified (CNC) room at minimum; if a biosafety cabinet and other 
large equipment (e.g., centrifuge) are required, then the room will 
need to be even larger and ISO certified as well. Additionally, due 
to its large lever arms and the large torque required to manipu-
late items as heavy as CF40s, the Nunc Automatic Cell Factory 
Manipulator System may potentially run into more structural 
issues with repeated use, as opposed to the Quantum’s small and 
highly stable peristaltic pumps.
While the Quantum certainly optimizes the manufacturing pro-
cess and makes it more compact, it should be emphasized that more 
than just a few Quantum units are required to produce enough len-
tiviral vector for phase 2 or phase 3 clinical trials, which sometimes 
warrant batch sizes comprised of hundreds of liters. Furthermore, 
Centricon centrifugal units are nonsterile, making them unsuit-
able for clinical biologics manufacturing. Rather than providing 
 ready-to-use solutions for large-scale clinical manufacturing, how-
ever, our primary aim is to provide a proof of principle and explore 
new manufacturing and processing methods on different culture 
platforms. This and subsequent experiments in various systems 
could potentially lead to an even more efficient method capable of 
providing the amount of product needed for clinical trials.
For future studies, we plan to extend the vector manufactur-
ing capability to other gene therapy vectors that can be manu-
factured using plasmid transfection methods. Additionally, we 
are exploring sterile concentration methods suited for handling 
large product volumes in an aseptic environment as well as fur-
ther minimizing time spent in open culture to create the possibil-
ity of generating a truly clinical-grade vector. Further exploration 
of the Quantum system’s capabilities will also include the manu-
facturing of novel clinical-grade cell types such as induced plu-
ripotent stem cells and vector transduced cells for use in  clinical 
trials.
MATeRIAlS AND MeThODS
Quantum hollow fiber bioreactor
The Quantum bioreactor (Terumo BCT, Lakewood, CO) is a computer con-
trolled, closed system automated device originally engineered for cultur-
ing and large scale expansion of cellular products. It consists of a single 
use disposable set with built in fluidics, a hollow fiber cartridge, bags for 
product loading and harvesting, filtering media and waste containment. 
With the door closed, the unit itself is able to regulate temperature and 
functions as an incubator. As shown in Figure 1, the hollow fiber cartridge 
consists of two separate circulation loops incorporating both an intracapil-
lary loop (IC) and an extracapillary loop (EC) that can be used to load cells 
or add and remove media, reagents and waste. A computerized touch 
screen provides the user access to the software allowing the parameters 
of a preprogrammed task to be defined and modified (circulation rates, 
washes, harvesting) and also allows for the creation of completely new 
custom tasks that can be saved. Required gases can be pumped into the 
system via external tanks and tubing that runs through integrated gas fil-
ters at the device.
Bioreactor preparation
The cell expansion set and cartridge were fluid primed, coated with fibro-
nectin and conditioned with media initially. The day before cell seeding 
into the hollow fiber cartridge, a cell expansion set was loaded into the 
Quantum system and the “Load Cell Expansion Set” program was exe-
cuted. For the priming step, 4 liters of Dulbecco’s phosphate-buffered 
saline (GE Healthcare, Little Chalfont, UK)  were transferred, using a 
peristaltic pump inside a biosafety cabinet into a media bag which was 
sterile-welded onto the bioreactor system. The “Prime Expansion Set” 
program task was executed and the expansion set-associated tubing 
and fluidics were filled with Dulbecco’s phosphate-buffered saline. Next, 
100 ml of 0.5 mg/ml human fibronectin (BD Biosciences, Franklin Lakes, 
NJ) in Dulbecco’s phosphate-buffered saline were transferred into a cell 
inlet bag, which was welded onto the bioreactor system, loaded into 
the cartridge using the “Coat Bioreactor” program task and allowed to 
incubate for 16 hours at 37 °C. After incubation, an “IC/EC Washout” task 
was performed to remove excess fibronectin. To condition the cartridge, 
4 liters of HEK-293T culture media were transferred into a 4 liters media 
bag which was sterile-welded onto the system. The “Condition Media” 
program task was run, while equilibrating and maintaining a gas mixture 
containing 5% CO2 with culture media inside the bioreactor.
Cell culture
Previously, clinical grade HEK 293T cells were obtained from the National 
Gene Vector Biorepository, Indianapolis, Indiana. Cell cultures were pas-
saged in T225 tissue culture flasks (Corning, Corning, NY) to maintain expo-
nential growth phase in D10 media consisting of Dulbecco’s modified Eagles 
medium/high glucose (GE Healthcare, Little Chalfont, UK) with 10% fetal 
bovine serum (GE Healthcare) and 200 mmol/l GlutaMAX (Life Technologies, 
Gibco). Four liters of culture media were prepared in a 4 l media bag for 
maintenance of the bioreactor run. To seed the hollow fiber bioreactor car-
tridge, 1 × 109 HEK 293T cells were trypsinized and resuspended into 100 ml 
of culture media, loaded into a cell inlet bag and seeded into the hollow fiber 
bioreactor cartridge previously coated with fibronectin. Cells were allowed 
to attach for 24 hours before transfection by an “Attach Cells” task prepro-
grammed into the system. Prior to transfection in the bioreactor, the cells 
were incubated for 24 hours to allow for attachment. During attachment and 
for the rest of the run, media samples were taken from the EC sampling port 
Table 4 Viral titer comparison between lentiviral vector 
production methods
Viral titer (vg/ml) T225 flasksa CF10b Bioreactorc
Trial #1 1.90 × 108 2.02 × 108 1.915 × 108
Trial #2 2.03 × 108 3.17 × 108 2.790 × 108
Trial #3 1.88 × 108 N/A 1.025 × 108
Trial #4 1.24 × 108 N/A N/A
Trial #5 1.60 × 108 N/A N/A
Mean 1.73 × 108 2.60 × 108 1.91 × 108
Standard 
deviation
3.16 × 107 8.13 × 107 8.83 × 107
Variance 9.96 × 1014 6.61 × 1015 1.64 × 1016
aEach trial performed in T225 flasks involved two T225 flasks,  beach trial 
performed in CF10s involved a single CF10, and ceach trial performed in the 
bioreactor involved a single hollow-fiber cartridge.
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for lactate measurements using a Lactate Plus meter and test strips (Sports 
Resource Group, Minneapolis, MN) as an indicator of cell growth. For small-
scale transfections, T225 tissue culture flasks were seeded with 2.5 × 107 cells 
per flask and incubated for 24 hours. Each trial conducted in T225 flasks con-
sisted of two flasks. In addition, HEK-293T cells were also seeded into CF10s 
at 7 × 108 cells per stack in approximately 1.3 l of D10 media.
Plasmids
For transfections, lentiviral vectors were generated using the following 
plasmids: (i) pMDG-VSVG envelope encoding a vesicular stomatitis virus, 
G glycoprotein. (ii) pCMV-dR8.91 packaging plasmid containing the (gag/
pol) structural and polymerase genes. (iii) pMNDU3-OKSM-PGK-EGFP-WPRE 
transgene construct containing a polycistronic, 4-factor iPSC induction 
cassette (OCT4, KLF4, SOX2, and c-Myc) and a PGK promoter driven EGFP 
green fluorescent protein. For the bioreactor, 10 mg preps of plasmid DNA 
were grown up in chemically competent DH10B Escherichia coli obtained 
from Life Technologies and purified using an Endotoxin-Free Giga-Prep Kit 
(Qiagen). Purified plasmids had endotoxin levels ≤0.5 EU/ml.
Calcium-magnesium phosphate transfection
To perform the large-scale bioreactor transfection, a triple transfection 
of pMDG-VSVG, pCMV-dR8.91 and pMNDU3-OKSM-PGK-EGFP-WPRE was 
performed. Plasmids were used at a ratio of 5:5:1 (3.0 mg of dR8.91 pack-
aging plasmid/3.0 mg of OKSM-EGFP transfer plasmid/600 µg of VSVG). 
Briefly, a two-part transfection reagent mix was prepared based on plas-
mid concentrations (Table 3). The volume of each reagent was adjusted to 
a volume totaling the approximately 180–200 ml capacity of the bioreactor 
cartridge’s IC loop. All three plasmids were mixed in one vessel containing 
41.90 ml of sterile water, 29.70 ml of 2 mol/l CaCl2 (Sigma-Aldrich, St. Louis, 
MO) and 7.20 ml of 2 mol/l MgCl2  (Sigma-Aldrich, St. Louis, MO). In a sepa-
rate container, 116.60 ml of 2×  phosphate-containing 4-(2-hydroxyethyl)-1- 
piperazineethanesulfonic acid-buffered saline (HeBS) solution was pre-
pared. The two mixtures were combined and quickly loaded into a cell inlet 
bag, precipitated and then loaded into the bioreactor cartridge using the 
“Add Bag Contents” preset task to transfect the cells. A 47 ml chase with 
complete Dulbecco’s modified Eagles medium was performed with the IC 
waste valve closed and the EC waste valve open to ensure that the reagent 
mix was in close proximity with the walls of the hollow fibers and in direct 
contact with the cells. Subsequently, the “Attach Cells” task was run a sec-
ond time to allow media to be fed to the cells via the EC loop while leav-
ing the IC loop, containing the cells and transfection mix, undisturbed. The 
system was allowed to incubate at 37 °C and 5% CO2 for approximately 15 
hours. For transfections in CF10s, 700 µg of dR8.91 packaging and OKSM-
EGFP transfer plasmids were used with 140 µg of VSVG envelope plasmid. 
Transfections performed in T225 flasks used 25 µg each of the dR8.91 and 
OKSM-EGFP plasmids together with 5 µg of VSVG per flask. For transfec-
tions in the bioreactor, a calcium-magnesium phosphate transfection mix 
was used, and all transfections were performed overnight. The following 
day, the transfection mixes were removed from the bioreactor, cell stacks 
and flasks and replaced with serum free UltraCULTURE media (Lonza, Basel, 
Switzerland) for harvesting vector.
Vector harvest and downstream processing
Lentiviral vector produced from HEK-293T cells grown in the bioreactor 
was collected over 36 hours by continuous perfusion of serum free media 
through the IC loop and into a 4 l collection bag, transferred to sterile 1 l 
media bottles, and stored at −80 °C. Similarly, the vector-containing super-
natants from the CF10s were collected and pooled as a single harvest into 
sterile bottles, and stored at −80 °C. Vector-containing supernatants from 
the T225 runs were pooled together and taken directly for concentration 
and titer measurement.
Before treatment with Benzonase Nuclease (Sigma-Aldrich, St. Louis, MO), 
the supernatants were clarified through a 0.45-μm media filter (Corning, 
Corning, NY). Benzonase Nuclease was added to each of the viral super-
natant collections in a concentration of 50 units/ml and incubated in a 
standard 5% CO2, 37 °C incubator for one hour to eliminate residual plas-
mids from the transfections. Vector supernatants from the T225 flasks were 
pooled together to obtain a total volume of 60 ml prior to concentration. 
Vector supernatants from the CF10s and bioreactor were frozen at −80 °C 
after taking a 60 ml sample for testing. The 60 ml samples were concentrated 
by spin-filtration using Centricon Plus-70 (Millipore, Billerica, MA) centrifu-
gal units with a 100-kDa cutoff. The spin-filtration units were centrifuged at 
3,500 rpm for 30 minutes, then inverted and placed into collection cups that 
were centrifuged for 5 minutes at 1,100 rpm. Approximately 300 µl of con-
centrated vector was collected from each of the spin-filtration units.
Particle titer by qPCR
Lentiviral vector RNA was titered by qPCR using a qPCR Lentivector Titration 
Kit (Applied Biological Materials, Richmond, Canada) according to the 
manufacturers’ protocol. Briefly, samples were diluted 1:10 and 1:100 in 
phosphate-buffered saline prior to lysis. Viral lysis was performed using 2 µl 
of diluted viral supernatant added to 18 µl Virus Lysis Buffer provided. The 
mixture was incubated for 3 minutes at room temperature to obtain the viral 
lysate. Reactions were set up in triplicate and a no template control was used. 
The qRT-PCR program was performed on an Applied Biosystems 7300-Real 
Time PCR system using the following qRT-PCR parameters: 1 cycle of reverse 
transcription was performed at 42 °C for 20 minutes, 1 cycle of enzymatic 
activation was performed at 95 °C for 10 minutes, 40 cycles of denaturation 
was performed at 95 °C for 15 seconds, and 40 cycles of annealing/extension 
was performed at 60 °C for 1 minute. Sample titers were calculated from Ct 
values using the following equation:
Titer of viral lysate  =  5 × 107/23(Ctx-Ct1)/(Ct2-Ct1) * (dilution factor) where Ctx 
equals the average of three Ct sample values, Ct1 equals the average of three 
Ct values from Standard 1 values and Ct2 equals the average of three Ct values 
from Standard 2.
Transducing titers were not performed as part of our study.
Data presentation and statistical analysis
All values presented in Figure  2 represent the mean, with the standard 
error of the mean represented by error bars. The number of experiments 
performed in each culture platform is shown in Table 4. All significant dif-
ferences were evaluated using Welch’s t-test, comparing experimental data 
obtained from production runs performed in CF10s and the bioreactor to 
data obtained using pre-established protocols in T225 flasks.
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